Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects
NCT03631199 · Novartis Pharmaceuticals · PHASE3 · terminated · last registry update 2026-06-17 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Results of primary analysis showed addition of canakinumab to combination treatment did not improve tumor response or overall survival; the decision to stop the trial was not due to safety concerns” | Open Targets' class: negative | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL1B in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
No results, stops or Phase 3 starts on the same target in that window.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision